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Introduction
Lamivudine is a pyrimidine nucleoside originally devel-
oped as an antiretroviral drug. It is a cytidine analog
that metabolizes intracellularly to lamivudine triphos-
phate, which inhibits hepatitis B DNA polymerase as
well as human immunodeficiency virus (HIV) reverse
transcriptase. Lamivudine is an effective monotherapy
for the treatment of chronic hepatitis B, and in com-
bination with other antiretroviral drugs for the treat-
ment of HIV-1 infection. Lamivudine has high oral
bioavailability and a relatively long plasma half-life
(5–7 hours), which makes once-daily dosing feasible
for patients with chronic hepatitis B.1
Lamivudine has proved beneficial in patients with
chronic hepatitis B, and the effectiveness of lamivu-
dine in the treatment of chronic hepatitis B has been
confirmed in delaying clinical progression in patients
with chronic hepatitis B and advanced fibrosis or cir-
rhosis.2–4 But there are few reports on the treatment
of chronic hepatitis B with acute exacerbation during
pregnancy. Here, we report a case of chronic hepatitis B
carrier gravida who was treated with lamivudine from
17+1 gestational weeks and delivered a male baby
weighing 3,314 g with good Apgar scores at 38+3 ges-
tational weeks. The newborn did not have congenital
anomalies, and the neonatal growth was within normal
reference ranges.
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Case Report
This G2P1, 32-year-old, female was an HBV carrier.
After the patient gave birth to her first baby, a physi-
cal check-up revealed serum alanine aminotransferase
(ALT) of 571 U/L, aspartate aminotransferase (AST)
of 165 U/L, HBsAg(+), HBeAg(+) and anti-HCV(−).
Under the impression of chronic hepatitis B with acute
exacerbation, she received a first course of lamivudine
therapy 100 mg/qd for 17 months. At the end of the
first course of lamivudine therapy, HBeAg seroconver-
sion went from positive to negative, but serum ALT
and AST levels were 3–4 times normal. Under the
clinical impression of YMDD motif mutation of the
HBV polymerase gene, the patient stopped lamivudine
therapy.
After discontinuation of lamivudine, she became
pregnant. HBeAg became positive again. The serum
liver enzyme ALT was as high as 1,570 U/L at 13+1
gestational weeks. She began receiving the hepato-
protective agent silymarin, 150 mg bid, at 13+2 gesta-
tional weeks. The serum liver enzyme AST remained
at 757 U/L at 15+0 gestational weeks, but flared up
to ALT 2,230 U/L and AST 2,250 U/L at 17+1 ges-
tational weeks (Figure 1). The measurement of serum
HBV DNA during the second course of lamivudine
treatment was performed by a quantitative PCR assay
(Amplicor™ HBV monitor test; Roche Diagnostics).5
HBeAg was positive, and the HBV-DNA test revealed
serum HBV-DNA of 7.31 × 108 copies/mL at 17+1
gestational weeks. Total serum bilirubin was 0.7 mg/
mL and international normalized ratio at the time was
0.93. A second course of lamivudine 100 mg/qd and
silymarin 150 mg bid was initiated. At 21+0 gesta-
tional weeks, serum liver enzymes showed a gradual
decline to ALT 341 U/L and AST 91 U/L, while
HBeAg(+) converted to (–) and anti-HBe(–) con-
verted to (+). Further treatment with lamivudine
100 mg/qd continued for 3 months. Serum HBV-
DNA decreased to 3.19 × 102 copies/mL at 36+6
gestational weeks. The patient experienced pruritic
urticarial papules and plagues of pregnancy (PUPPP)
at 37+6 gestational weeks and was given prednisolone
5 mg/qd for 7 days, and the PUPPP lesions subsided.
Hepatitis B marker was re-checked and revealed
HBsAg(+), HBeAg(–) and anti-HBeAb(+). Interna-
tional normalized ratio was 0.99 and total bilirubin was
0.4 mg/mL. Spontaneous delivery of a male baby
weighing 3,314 g occurred at 38+3 gestational weeks
with Apgar scores of 8 and 9 at 1 and 5 minutes,
respectively. The mother experienced no lactic acidosis
throughout the whole course of pregnancy.
The neonatal physical check-up revealed no con-
genital anomalies, and fetal growth was within normal
reference ranges. Passive immunization with hepatitis B
immune globulin 0.5 mL was injected immediately
after delivery. The serum liver enzymes of the gravida
were ALT 138 U/L and AST 40 U/L 2 months 
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Figure 1. Clinical course of serum liver enzyme and HBV DNA profiles of the gravida complicated with chronic hepatitis B with acute
exacerbation. HBV = hepatitis B virus; ALT = alanine aminotransferase; AST = aspartate aminotransferase.
postpartum. But the HBV-DNA test revealed increased
serum HBV-DNA of 5.76 × 105 copies/mL, and was
positive for YMDD mutation.
Discussion
Using lamivudine for the treatment of a hepatitis B
carrier with chronic exacerbation during the second
trimester of pregnancy showed promising results. The
liver enzymes decreased, and the newborn was free of
teratogenic effects. In another report, no congenital
anomalies were found in a large cohort of HIV-1-
infected women who received antiretroviral therapy
during pregnancy.6 The risk of an adverse outcome
due to lamivudine treatment during pregnancy was
not associated with the use of antiretroviral regimens
overall.7
The nucleoside reverse-transcriptase inhibitors are
generally well tolerated across the placenta. These
agents have not been shown to be teratogenic in 
animals in concentrations similar to those used in
humans. The rate of birth defects in more than 400
women exposed to zidovudine or lamivudine during
the first trimester of pregnancy as reported to the
Antiretroviral Pregnancy Registry was no higher 
than the rate of birth defects of women who were
exposed to similar drugs after the first trimester as
reported in the Metropolitan Atlanta Congenital
Defects Program of the Centers for Disease Control
and Prevention.8 Lamivudine is helpful in preventing
maternal–infant HBV transmission and may reduce
the complications of HBV-infected patients who
become pregnant.9
Nucleoside reverse-transcriptase inhibitors that bind
to mitochondrial DNA polymerase gamma can cause
mitochondrial dysfunction, which may manifest as
myopathy, cardiomyopathy, neuropathy, lactic acido-
sis, or fatty liver.8 Toxic effects of long-term therapy
with nucleoside reverse-transcriptase inhibitors may
be enhanced in women who become pregnant. Three
deaths and additional cases of lactic acidosis and he-
patic failure have been noted among pregnant women
who began receiving stavudine and didanosine along
with other drugs before pregnancy.8 Clinical findings
are similar to those in acute fatty liver of pregnancy, a
syndrome that is more frequent among women with
heterozygous defects of mitochondrial fatty-acid me-
tabolism who are carrying fetuses that are homozy-
gous for the same defect.8
The major limitation of lamivudine treatment is
the high rate of viral resistance related to mutations 
in the YMDD motif of the HBV polymerase gene.
The emergence of lamivudine-resistant mutants is
usually associated with a breakthrough of hepatitis,
with moderately increased levels of serum HBV-DNA
and ALT, although these levels may be lower than 
the baseline (pretreatment) for several months.10 The
first manifestation of antiviral resistance is virologic
breakthrough, which is defined as a > 1 log 10 (10-
fold) increase in serum HBV DNA from nadir during
treatment in a patient who had an initial virologic
response.11 In patients who develop resistance to
lamivudine, adefovir should be given immediately
once serum ALT level increases. This is especially im-
portant in patients with cirrhosis who are at risk of
hepatic decompensation. In order to detect the resis-
tance early (before the appearance of detectable serum
HBV-DNA by standard assays and before the increase
in serum ALT level), monitoring of serum HBV-DNA
level by a sensitive assay may be useful. An increase 
in serum HBV-DNA level of more than 1 log unit
generally reflects the appearance of a resistant mutant
and allows institution of therapy with adefovir several
months before the increase in serum ALT level is
observed.10 The reuse of lamivudine after the emer-
gence of YMDD mutation is still effective in control-
ling the exacerbation of chronic hepatitis B. The
consideration for reusing lamivudine instead of ade-
fovir in our patient was that lamivudine, with a preg-
nancy risk class B, is less risky than adefovir, which has
a class C rating in terms of pregnancy risk.
Currently, 2 types of HBV DNA assays are avail-
able as commercial kits: a signal amplification assay 
in which the signal emitted from captured HBV DNA
is amplified, and a target amplification assay which
involves amplification of the target HBV DNA se-
quence.5 Quantification of HBV DNA has numerous
practical applications, including assessment of disease
severity and prognosis, monitoring therapeutic effi-
cacy, and identifying treatment resistance. The devel-
opment and widespread implementation of sensitive
HBV DNA assays have had a significant impact on the
ability of physicians to evaluate hepatitis B patients
and manage antiviral therapy.5
Lamivudine has been found to be an effective
treatment strategy for chronic HBV. However, its use
is not recommended during the first trimester because
animal studies have shown it to be lethal to rabbit
fetuses.9 Mothers who carry the hepatitis B virus are
encouraged to breastfeed their babies. However, it is
recommended that breastfeeding start after adminis-
tration of hepatitis B immune globulin but not neces-
sarily before the first hepatitis B vaccination. Mothers
who want to breastfeed should take good care of their
nipples to avoid bleeding.
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